All In Biotech

Drug Trial Radar · NCT01518998

A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension

Last checked: Nov 19, 2026Latest source record: Jul 1, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

420

Actual

Start

Aug 2011

Primary completion

Oct 2013

Study completion Nov 2013

Sponsor

Sponsor type
Industry
Collaborators
Gachon University Gil Medical Center; The Catholic University of Korea; Kyungpook National University Hospital; Daegu Catholic University Medical Center; Wonkwang University Hospital; Wonju Severance Christian Hospital; Korea University Guro Hospital; DongGuk University; Yeungnam University Hospital; Chonnam National University Hospital; Cheil General Hospital and Women's Healthcare Center; Chungnam National University; Asan Medical Center; Seoul National University Bundang Hospital; Inha University Hospital; Seoul National University Hospital; Inje University; Samsung Medical Center; Pusan National University Yangsan Hospital; Soon Chun Hyang University; Catholic University of Korea Saint Paul's Hospital; Hallym University Kangnam Sacred Heart Hospital; Jeju National University Hospital; Hanyang University Seoul Hospital; Kangbuk Samsung Hospital
First posted
Jan 26, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Factorial
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan

Conditions

  • Hypertension

Interventions

  • Fimasartan , Amlodipine, PlaceboDrug

    Fimasartan 60mg, Fimasartan 30mg, Amlodipine 5mg, Amlodipine 10mg, Placebo, Fimasartan 60mg/Amlodipine 5mg combination, Fimasartan 60mg/Amlodipine 10mg combination, Fimasartan 30mg/Amlodipine 5mg combination, Fimasartan 30mg/Amlodipine 10mg combination

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sitting Diastolic Blood PressureTime frame: 8weeks from baseline visit

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Samsung Medical Center

    Seoul, Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.